Chimeric Antigen Receptor (CAR)-T Cell Therapy for Patients With Hematologic Malignancies
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2019
Price : $35 *
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Tisagenlecleucel (Primary)
- Indications Diffuse large B cell lymphoma; Haematological malignancies; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 02 Jan 2019 Status changed from not yet recruiting to recruiting.
- 03 Dec 2018 Planned End Date changed from 1 Jun 2028 to 1 Jul 2028.
- 03 Dec 2018 Planned primary completion date changed from 1 Jun 2028 to 1 Jul 2028.